Status:
UNKNOWN
Administration of High Dose Thiotepa and Melphalan With Autologous Hematopoietic Stem Cell Transplant in Children and Adolescents With Solid Tumors
Lead Sponsor:
Rabin Medical Center
Conditions:
Central Nervous System Tumors
Tumors
Eligibility:
All Genders
1-21 years
Phase:
NA
Brief Summary
The prognosis of children and adolescents with high risk tumors of the central nervous system and other miscellaneous solid tumors is poor despite modern treatment protocols. Frequently, physicians su...
Detailed Description
Despite progress in the treatment of children and adolescents suffering from solid tumors and tumors of the CNS, patients with metastatic disease (or with disease with other high risk features) contin...
Eligibility Criteria
Inclusion
- Age 1-21 years
- CNS tumors, hepatic tumors and other solid tumors that are chemosensitive
- Minimal disease as determined by either radiological studies or biochemical markers (as determined by treating physician).
- Consent of patient or surrogate.
Exclusion
- Not pregnant or nursing
- Fertile patients must use effective contraception
- No known HIV or AIDS infection
- No active bacterial, fungal, or viral infection
- No medical condition that would preclude study treatment
- Positive pregnancy test or failure to use contraceptives.
- Creatinine \>1.5 times limit of normal for age
- SGOT or SGPT more than 3 times normal.
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00607984
Start Date
June 1 2006
Last Update
February 6 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Schneider Children's Medical Center of Israel
Petah Tikva, Israel, 49202